DIA today announced a partnership with Thomson Reuters to build upon its library of eLearning modules tailored to professionals from around the world who are involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products.
DIA members and customers will now have access to Thomson Reuters IDRAC® Regulatory Affairs eLearning Modules to help them navigate the ever-changing global regulatory landscape.
“Our constituents represent a diverse group of global health care professionals all coming together to achieve their common professional aspirations essential to innovation in today’s health care environment,” says DIA Worldwide Executive Director Paul Pomerantz. “IDRAC’s global reach, depth of analysis, and local expertise supports our commitment to providing in-depth knowledge of every regulation that could affect the discovery, development, and delivery of health care products around the world.”
-
DIA and IDRAC will deliver elearning modules focusing on a variety of topics, including:
- Access to Unapproved Drugs through Compassionate Use
- Regulatory Requirements for the Conduct of Clinical Trials in Europe
- Orphan Drugs in Europe, USA and Japan
- Regulatory Requirements for the Submission of Investigational New Drug Applications in the USA (INDs)
- Meeting Opportunities with Regulatory Agencies
- Introduction to the European Union Institutions and Regulatory Authority
- Introduction to US Institutions and Regulatory Authority (FDA)
- Introduction to Japanese Institutions and Regulatory Authorities
- Overview of the CTD and the eCTD
- Introduction to the International Conference on Harmonization (ICH)
- The Regulatory Development Cycle of a Drug
- Basics of Pharmacovigilance
- Basics of Clinical Trials
- How to Register Medicinal Products through the Centralized Procedure
- How to Register Medicinal Products through the Mutual Recognition Procedure
- How to Maintain Marketing Approvals in Europe for Centrally Authorized Products
- How to Register a New Drug in the USA
- How to Register Medicinal Products through the Decentralized Procedure
DIA eLearning modules can easily accommodate employee learning with 24/7 access. DIA courses are instructionally engineered for effective, interactive, and self-paced learning.
“Thomson Reuters has years of experience in partnering with DIA to bring regulatory news and FDA Advisory Committees’ meetings coverage to its members,” says Claude Basset, vice president at Thomson Reuters. “We’re excited to extend this partnership to provide DIA with eLearning content backed by IDRAC’s recognized expertise in regulatory affairs.”
ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.
THOMSON REUTERS
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.